





About Amplimexon® (imexon, inj.).
Amplimexon®,
an anticancer drug with a novel mechanism of action, is minimally
myelosuppressive only at the highest doses and overcomes multi-drug
resistance.
The drug is a member of the cyanoaziridine class of compounds, and it is
believed that it induces oxidative stress in cancer cells by reducing
intracellular levels of thiols, resulting in mitochodrial damage and
apoptosis. It has also been shown in vitro and in vivo to synergize with
several classes of anticancer drugs, including alkylating agents,
antimetabolites and taxanes.
AmpliMed has completed three Phase I dose escalation studies in patients
with a variety of refractory solid tumors and myeloma. For these studies,
the toxic effects, pharmacokinetic behavior and maximum tolerated dose and
schedule for Amplimexon was determined. Maximum tolerated dose and schedule
established as a result of the studies was a 45 minute infusion, 5 days
every two weeks or 5 days every three weeks. The drug was well tolerated,
with generally mild and manageable nausea, vomiting, constipation, diarrhea
and fatigue being the most common side effects at the maximum tolerated
doses.
AmpliMed is currently enrolling a series of indication-directed clinical
trials in which Amplimexon® is being administered in combination with
currently available cancer chemotherapies including dacarbazine (DTIC®), gemcitabine (Gemzar®) and docetaxel (Taxotere®). Indications being studied
include pancreatic adenocarcinoma, malignant melanoma, breast, lung and
prostate cancer.
For more information on AmpliMed clinical trials, please click here.
Publications: Concerning Amplimexon and Amplizone
A newsletter concerning recent events at AmpliMed is available..
